A Phase 3 interventional study of Placebo and Rufinamide in Epilepsy, sponsored by Eisai Inc.. Completed at 77 sites in United States. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Epilepsy by Eisai Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Epilepsy · Eisai Co., Ltd..
Among the 51 studies in Epilepsy by Eisai Co., Ltd., this one is the 5th largest by enrollment of the 42 interventional ones that give a count, is one of 7 that started in 2006, is one of 17 in phase 3, and was the 8th registered.
1,848 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →None of the 51 studies in Epilepsy by Eisai Co., Ltd. is open now. The open studies under Epilepsy, anywhere →
Of the 283 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 138 take children under 18; 55 take healthy volunteers.
This study: 12 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 356 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 83 across the 42 interventional studies, 200 across the 7 observational. Of the 48 that completed or were terminated, 30 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
1 of the studies in Epilepsy by Eisai Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04015141Eisai Inc.A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy | 2027-04-06 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies in Epilepsy by Eisai Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For 12-day Titration Phase and 12 week Maintenance Phase, placebo tablets matching to rufinamide 400 mg oral tablets will be administered according to the same regimen scheme as described for rufinamide. For 12-day Titration Phase, 1 matching placebo tablet will be administered twice daily and increased by 1 tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily.
Drug: Placebo
For the 12-day Titration Phase, rufinamide will be administered orally in doses starting with 400 milligram (mg) twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the 12 week Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
Drug: Rufinamide
For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
Also known as: E2080, BANZEL
Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase
Seizure data was collected via patient diary, which was used to record daily seizure count and type. Intent-to-treat (ITT) population: All randomized participants who had baseline Patient Seizure Diary data and had at least completed the titration period.
Time frame: Baseline, Days 13 to 96
Percentage of Participants With 50% or Greater Reduction in Total Partial Seizure Frequency Per 28 Days During the Maintenance Phase Relative to the Baseline Phase
Seizure data was collected via patient diary, which was used to record daily seizure count and type.
Time frame: Baseline, Days 13 to 96
Log10 Transformed Total Partial Seizure Frequency Per 28 Days During the Baseline Phase and Maintenance Phase
Total partial seizure frequencies per 28 days during the double-blind Maintenance and Baseline Phases were transformed using logarithms to the base 10 (log10), because it was expected from previous studies that the results would not be normally distributed.
Time frame: Days 13 to 96
Reduction From Baseline in Total Partial Seizure Frequency Rate (RRATIO) During Maintenance Phase
RRATIO= 100\*(T-B)/(T+B) where T= total seizure frequency per 28 days during the Maintenance Phase, and B=total seizure frequency per 28 days during the Baseline Phase.
Time frame: Baseline, Days 13 to 96
| Milestone | Rufinamide | Placebo |
|---|---|---|
| Started | 176 | 180 |
| Completed | 139 | 156 |
| Not completed | 37 | 24 |
| Withdrew: Medication noncompliance | 0 | 3 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Request of the investigator or sponsor | 0 | 1 |
| Withdrew: Withdrawal by subject | 7 | 4 |
| Withdrew: Adverse event | 27 | 12 |
| Withdrew: Other | 1 | 2 |
Seizure data was collected via patient diary, which was used to record daily seizure count and type. Intent-to-treat (ITT) population: All randomized participants who had baseline Patient Seizure Diary data and had at least completed the titration period.
| Percentage change | Rufinamide | Placebo |
|---|---|---|
| Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase | -23.25 (-100.0 to 725.6) | -9.80 (-100.0 to 864.3) |
Seizure data was collected via patient diary, which was used to record daily seizure count and type.
| Percentage of Participants | Rufinamide | Placebo |
|---|---|---|
| Percentage of Participants With 50% or Greater Reduction in Total Partial Seizure Frequency Per 28 Days During the Maintenance Phase Relative to the Baseline Phase | 32.5 | 14.3 |
Total partial seizure frequencies per 28 days during the double-blind Maintenance and Baseline Phases were transformed using logarithms to the base 10 (log10), because it was expected from previous studies that the results would not be normally distributed.
| Seizures per 28-days (log-transformed) | Rufinamide | Placebo |
|---|---|---|
| Log10 Transformed Total Partial Seizure Frequency Per 28 Days During the Baseline Phase and Maintenance Phase | 0.98 ± 0.675 | 1.13 ± 0.520 |
RRATIO= 100\*(T-B)/(T+B) where T= total seizure frequency per 28 days during the Maintenance Phase, and B=total seizure frequency per 28 days during the Baseline Phase.
| RRATIO | Rufinamide | Placebo |
|---|---|---|
| Reduction From Baseline in Total Partial Seizure Frequency Rate (RRATIO) During Maintenance Phase | -18.76 ± 37.841 | -6.90 ± 24.869 |
Collected over All AEs were collected throughout the study from the time of consent to follow-up visit or 30 days after study drug discontinuation, whichever was longer (up to approximately 3 years and 3 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rufinamide | 0/176 (0%) | 6/176 (3.4%) | 101/176 (57.4%) |
| Placebo | 0/180 (0%) | 7/180 (3.9%) | 66/180 (36.7%) |
| Event | Rufinamide | Placebo |
|---|---|---|
| ConvulsionNervous system disorders | 2/176 | 2/180 |
| NauseaGastrointestinal disorders | 1/176 | 0/180 |
| VomitingGastrointestinal disorders | 1/176 | 0/180 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/176 | 0/180 |
| Weight decreasedInvestigations | 1/176 | 0/180 |
| Complex partial seizuresNervous system disorders | 1/176 | 1/180 |
| Coordination abnormalNervous system disorders | 1/176 | 0/180 |
| LethargyNervous system disorders | 1/176 | 0/180 |
| Transient ischaemic attackNervous system disorders | 1/176 | 0/180 |
| ContusionInjury, poisoning and procedural complications | 1/176 | 0/180 |
| Event | Rufinamide | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 47/176 | 15/180 |
| HeadacheNervous system disorders | 29/176 | 23/180 |
| FatigueGeneral disorders | 27/176 | 18/180 |
| NauseaGastrointestinal disorders | 22/176 | 9/180 |
| SomnolenceNervous system disorders | 22/176 | 13/180 |
| Upper respiratory tract infectionInfections and infestations | 6/176 | 15/180 |
| DiplopiaEye disorders | 14/176 | 2/180 |
| VomitingGastrointestinal disorders | 13/176 | 9/180 |
| ContusionInjury, poisoning and procedural complications | 9/176 | 5/180 |
| Age, Customized(participants) | Rufinamide | Placebo | Total |
|---|---|---|---|
| 12 to < 18 years | 15 | 21 | 36 |
| 18 to <65 years | 155 | 153 | 308 |
| >=65 years | 6 | 6 | 12 |
| Sex: Female, Male(Participants) | Rufinamide | Placebo | Total |
|---|---|---|---|
| Female | 92 | 97 | 189 |
| Male | 84 | 83 | 167 |
| Race/Ethnicity, Customized(participants) | Rufinamide | Placebo | Total |
|---|---|---|---|
| Black | 14 | 19 | 33 |
| White | 145 | 140 | 285 |
| Hispanic | 13 | 14 | 27 |
| Native American | 0 | 2 | 2 |
| Asian/Pacific Islander | 4 | 2 | 6 |
| Other | 0 | 3 | 3 |
Ran from Feb 2006 to primary completion in May 2009, 39 months.
Results were first posted in Feb 2013, 3 years 8 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 39 months is below that.
Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rufinamide